Cleanser Market Positioning Guide: Claims, Clinical Language & OEM Capabilities

Overview #

Cleanser is the most underestimated SKU in any skincare line. Brands spend months agonizing over serum actives and then brief us on a “gentle foaming cleanser” in a single paragraph. That’s backwards. The cleanser is the first product that touches skin every day — sometimes twice — and the claims you put on it either build a coherent brand story or quietly undermine everything else in your routine. We position cleansers differently depending on whether the brand is playing in barrier-repair, acne-control, brightening, or microbiome-friendly territory. The formulation decisions that support each of those positions are not interchangeable.

What “Cleanser” Actually Means at the Formulation Level #

Most brand owners come to us with a mood board and a one-liner: “clean, gentle, pH-balanced.” That’s a starting point, not a brief. The first question we ask is: what’s the skin concern your customer has before they apply anything else? Because that answer determines the surfactant system, the pH target, the rinse profile, and ultimately what you can defensibly say on pack.

There are roughly four cleanser archetypes we build most often: foaming gel (pH 5.0–6.0, SCI or sodium cocoyl isethionate base), low-foam cream (pH 4.5–5.5, amino acid surfactant dominant), oil-to-milk (anhydrous phase with emulsifying wax, no pH target until emulsification), and micellar water (pH 6.0–7.0, polysorbate-based). Each one supports a different claim architecture. You can’t credibly run a “microbiome-friendly” claim on a sulfate-based foaming gel at pH 7.2. We’ve had that conversation more than once.

The surfactant choice is where most of the cost lives. Sodium lauryl sulfate is cheap — roughly $1.20–$1.80/kg — but it’s become a liability for premium positioning. Amino acid surfactants like sodium lauroyl glutamate or sodium cocoyl glycinate run $8–$14/kg depending on grade and origin. That delta shows up in your COGS. At a 200kg batch, the surfactant cost difference alone can be $800–$1,200 per run. Brands targeting the $25–$45 retail price point can usually absorb it. Brands trying to hit $12 retail cannot, and we tell them that upfront.

Claims Architecture: What’s Defensible and What Isn’t #

This is where projects go sideways most often. A brand will request “clinically proven gentle” on a product we haven’t tested yet, or “dermatologist-tested” without specifying what that test actually measures. These aren’t just marketing decisions — they’re regulatory commitments, and the bar is different depending on where you’re selling.

For EU markets, any efficacy claim must be substantiated under EU Cosmetics Regulation 1223/2009. “Gentle” is a functional claim that requires either consumer perception data or instrumental measurement — typically TEWL (transepidermal water loss) or corneometry. “pH-balanced” is descriptive and generally defensible if you can show the finished product pH. “Microbiome-friendly” is still in grey territory across most markets; the EU has not issued formal guidance, and we advise brands to either back it with sequencing data or soften the language to “respects the skin’s natural balance.”

For the US, FDA Cosmetics Guidelines draw a hard line between cosmetic claims and drug claims. “Treats acne” is a drug claim. “Helps clear blemishes” or “removes excess oil” stays cosmetic. We’ve seen brands get this wrong on Amazon listings and face account suspensions. It’s not a formulation problem — it’s a claims drafting problem — but we flag it during brief review because it affects what actives we can include and at what concentration.

Here’s a claims comparison table we use internally when positioning cleansers across different brand tiers and target markets:

One thing we push back on consistently: brands that want to stack five claims on a single cleanser. “Gentle, brightening, anti-aging, microbiome-friendly, and acne-clearing” — that’s not a product, that’s a wish list. Each claim pulls the formulation in a different direction. Low pH for AHA exfoliation conflicts with microbiome-friendly positioning. High niacinamide for brightening can interact with certain preservative systems. We almost always push back on this brief and ask the brand to pick a primary claim and two supporting ones.

The Clinical Language Question #

Brands want clinical language. We understand why — it converts. But “clinically tested” and “clinically proven” are not the same thing, and the difference matters when a retailer’s compliance team reviews your dossier.

The most defensible clinical language for a cleanser comes from a properly designed consumer use study. One study we reference internally: a 28-day single-blind consumer use trial (n=42) using an amino acid-based gel cleanser at pH 5.2 showed a 23% improvement in self-assessed skin comfort scores and a 17% reduction in TEWL versus baseline. That’s the kind of data that supports “clinically tested for skin comfort” on pack. It doesn’t support “clinically proven to repair the barrier” — that’s a different claim requiring a different study design.

Instrumental studies cost more but give you harder numbers. A corneometry study measuring skin hydration 30 minutes post-cleanse, run on 30 subjects over 4 weeks, typically runs $8,000–$15,000 depending on the CRO and geography. Most indie brands skip this. Honestly, most of them should — the ROI only makes sense if you’re pitching into Sephora or a major pharmacy chain where the buyer will actually ask for the data.

For brands selling into China, NMPA Cosmetic Regulation has its own substantiation framework. Functional claims require filing with supporting data, and the NMPA has been tightening enforcement since 2021. “Whitening” claims in particular require specific approved actives at specified concentrations. We handle NMPA filing support for clients targeting the China market — it’s not optional if you want shelf placement in domestic retail.

Where Most Brands Get the Positioning Wrong #

The most common mistake: positioning a cleanser as a “treatment” product and then pricing it like one. Consumers will pay $45 for a serum with 0.3% retinol. They are much more resistant to paying $38 for a cleanser, even a technically sophisticated one, because the rinse-off format creates a perceived value problem. The active is on skin for 60–90 seconds before it goes down the drain.

This doesn’t mean you can’t charge a premium for a cleanser. It means the premium has to be justified by sensory experience, packaging, or brand story — not by active concentration. We’ve seen brands brief us on 5% niacinamide cleansers because they want to match their serum. The niacinamide is mostly rinsed off. The cost is real. The benefit is marginal at best.

What actually drives cleanser repurchase is texture, rinse feel, and fragrance (or deliberate fragrance-free positioning). These are formulation decisions, not marketing decisions. A cleanser that leaves skin feeling tight after rinsing will not be repurchased regardless of what the claims say. We spend more time on rinse profile optimization than most clients expect.

One pilot batch failed because we used a fragrance at 0.6% in a low-pH amino acid system and the fragrance destabilized the foam structure by week 6 of stability testing. We reformulated at 0.3% and the issue resolved. That’s the kind of thing you only learn by running the batches.

For brands interested in how active delivery intersects with rinse-off formats, our acid exfoliation technology documentation covers the pH and contact-time considerations in more detail. And if you’re building a microbiome-friendly cleanser line, the microbiome and probiotic skincare section covers the preservative and surfactant compatibility questions we get most often.

OEM Capability: What the Geography Question Actually Means #

We get asked regularly how our capabilities compare to European or US-based contract manufacturers. Honest answer: it depends on what you’re optimizing for.

On formulation sophistication, the gap has closed significantly. We run full stability programs per ICH Stability Guidelines — 40°C/75% RH accelerated, 25°C/60% RH long-term, freeze-thaw cycling — and our in-house analytical lab handles HPLC, GC, viscometry, and pH profiling. We’re ISO 22716 GMP certified, which is the baseline the EU requires for cosmetic manufacturing. Most of our Western-market clients are surprised by the documentation depth.

Where Western manufacturers have a genuine advantage: speed of regulatory dialogue for EU and US markets, and proximity for last-minute reformulation cycles. If you’re launching in 8 weeks and need three reformulation rounds, a local manufacturer is faster. We’re honest about that.

Where we have a structural advantage: raw material access and cost. We source amino acid surfactants, botanical extracts, and specialty actives at 30–50% lower cost than equivalent European suppliers, because we’re closer to the supply chain. That translates directly to your COGS. At MOQ 3,000 units, the landed cost difference on a premium amino acid cleanser can be $1.80–$2.40 per unit versus a comparable European OEM. At 10,000 units, that’s a meaningful margin difference.

The other thing we offer that most Western OEMs don’t: direct NMPA filing support if you want to sell into China simultaneously. That’s not a small thing if your brand has any ambition in the Asia-Pacific market.

We’re still not fully convinced that “made in Europe” commands the premium it once did in all markets. It still matters in certain luxury segments and certain Southeast Asian markets. But in the US DTC space and in the Middle East, we’ve seen it matter less and less over the past three years.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask every cleanser brief, because the answers determine everything downstream.

If you’re targeting EU or UK retail, we’ll build your substantiation dossier from day one — not as an afterthought. That means selecting a surfactant system that supports your primary claim, setting a pH target that’s both stable and claim-consistent, and designing the stability program around your launch timeline. Typical development timeline for a new cleanser SKU is 10–14 weeks from signed brief to stability-pass samples, assuming no major reformulation rounds.

If you’re targeting US DTC, the priority shifts to sensory differentiation and packaging. We’ll run rinse-feel panels internally and flag any texture issues before you see samples. We’ll also review your claims copy before you finalize it — not because we’re lawyers, but because we’ve seen enough FDA warning letters to know where the lines are.

MOQ for cleanser is typically 1,000–3,000 units depending on format and packaging complexity. Airless pump formats run higher MOQ because of tooling. Tube and flip-cap formats are more flexible. If you’re at early stage and need 500 units for a pilot, we can discuss — but the unit economics won’t be pretty, and we’ll tell you that upfront rather than let you get surprised by the invoice.

Frequently Asked Questions #

Q: We want to call our cleanser “pH-balanced” — is that a claim we can actually make?

Yes, and it’s one of the easier ones to substantiate. You just need finished product pH data showing the product sits in the 4.5–6.5 range, which aligns with skin’s natural pH. We document this as part of standard QC on every batch, so you’ll have the data automatically.

Q: Can we include salicylic acid in a cleanser and still call it a cosmetic in the US?

At 0.5–2.0%, salicylic acid in a rinse-off cleanser falls under the OTC drug monograph for acne in the US. That means you’re making a drug product, not a cosmetic — different labeling requirements, different manufacturing standards. If you want to stay cosmetic, we can include salicylic acid at sub-0.5% for mild exfoliation, but you can’t make acne claims. Most brands don’t realize this until we tell them.

Q: How long does stability testing take before we can launch?

Accelerated stability at 40°C/75% RH runs 12 weeks minimum for most markets. EU requires real-time data to support shelf life claims beyond 30 months. We can release product for sale after 12 weeks of accelerated data while long-term data accumulates, but you’re taking a calculated risk if the formula hasn’t been run before. For a genuinely new formula, we recommend 16–20 weeks before commercial launch.

Q: We’ve seen “microbiome-friendly” cleansers everywhere — is that a claim we can support?

It’s supportable but not straightforward. There’s no standardized test method that regulators have formally endorsed for this claim. What we typically do: run a preservative efficacy test (PET) at the minimum effective concentration, use a surfactant system with a low irritation index, and commission a consumer perception study (n≥30, 4 weeks) measuring skin comfort and balance. That gives you a defensible basis. The claim language matters too — “supports the skin’s natural microbiome” is softer and safer than “clinically proven microbiome-friendly.”

Q: What’s the realistic MOQ if we’re just starting out?

For a standard tube or pump bottle cleanser, our minimum is 1,000 units. Custom packaging — embossed tubes, airless dispensers, specialty closures — typically requires 3,000 units minimum because of tooling amortization. If you’re testing the market with 500 units, we can sometimes accommodate that on a stock packaging format, but the per-unit cost will be roughly 35–45% higher than at 3,000 units. We’d rather tell you that now than after you’ve approved the formula.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.